ClostraBio, Inc

Biotechnology ResearchIllinois, United States11-50 Employees

ClostraBio is dedicated to creating new dietary supplements for gut health, and new therapeutics to treat conditions such as inflammatory bowel disease (IBD) and food allergy. 

CLB101™ is a proprietary next-generation strain of Anaerostipes caccae that was launched in 2025 (www.clb101probiotic.com). Unlike conventional approaches, this revolutionary anaerobic probiotic offers continuous, localized production of butyrate directly in the lower gut.*

Butyrate, a vital short-chain fatty acid naturally produced by select healthy gut bacteria, plays a critical role in maintaining gut barrier integrity, reducing systemic inflammation, and supporting overall wellness. 

Finding effective options to supplement butyrate production, however, is challenging. Butyrate supplements have an unpleasant taste and odor. Importantly, small molecules like butyrate are absorbed in the upper intestine and are not guaranteed to survive the journey to the lower gut, 
leading to inefficacy and a loss of consumer trust. There are few butyrate-producing bacterial strains, and while ubiquitous probiotics, such as lactobacillus and bifidobacterium, may support gut health through alternative mechanisms, they are not direct butyrate-producers.

CLB101™ was developed in response to these gaps. By combining advanced microbiome science with next-gen probiotic technology, CLB101™ is redefining what’s possible in gut health—delivering measurable results and setting a new standard in functional supplementation.



*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease

Sign up for free to view info

Email Format Employee directory